Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus.
BACKGROUND
In a previous study, progesterone treatment of female monkeys immunized with live, attenuated SHIV89.6 abrogated the generally consistent protection from vaginal simian immunodeficiency virus (SIV) challenge. The mechanisms responsible for the loss of protection remain to be defined. The objective of the present study was to determine whether Depo-Provera administration alters protection from intravenous SIV challenge in SHIV-immunized female macaques.


RESULTS
Two groups of female macaques were immunized with attenuated SHIV89.6 and then challenged intravenously with SIVmac239. Four weeks before challenge, one animal group was treated with Depo-Provera, a commonly used injectable contraceptive progestin. As expected, SHIV-immunized monkeys had significantly lower peak and set-point plasma viral RNA levels compared to naïve controls, but in contrast to previously published findings with vaginal SIV challenge, the Depo-Provera SHIV-immunized animals controlled SIV replication to a similar, or even slightly greater, degree than did the untreated SHIV-immunized animals. Control of viral replication from week 4 to week 20 after challenge was more consistent in the progesterone-treated, SHIV-immunized animals than in untreated, SHIV-immunized animals. Although levels of interferon-gamma production were similar, the SIV-specific CD8(+) T cells of progesterone-treated animals expressed more functions than the anti-viral CD8(+) T cells from untreated animals.


CONCLUSIONS
Depo-Provera did not diminish the control of viral replication after intravenous SIV challenge in female macaques immunized with a live-attenuated lentivirus. This result contrasts with the previously reported effect of Depo-Provera(R) on protection from vaginal SIV challenge and strongly implies that the decreased protection from vaginal challenge is due to effects of progesterone on the genital tract rather than to systemic effects. Further, these results demonstrate that the effects of hormonal contraceptives on vaccine efficacy need to be considered in the context of testing and use of an AIDS vaccine.
Genescà
Meritxell
M
Center for Comparative Medicine, University of California Davis, Davis, California, United States of America.
McChesney
Michael B
MB
Miller
Christopher J
CJ
D000818:Animals; D017209:Apoptosis; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D003271:Contraceptive Agents, Female / Q000494:pharmacology; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006678:HIV / Q000235:genetics*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008251:Macaca; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D012367:RNA, Viral / Q000378:metabolism; D015302:Simian Immunodeficiency Virus / Q000378:metabolism*; D016211:Transforming Growth Factor alpha / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014613:Vaccines, Attenuated / Q000276:immunology
D003271:Contraceptive Agents, Female; D012367:RNA, Viral; D016211:Transforming Growth Factor alpha; D016212:Transforming Growth Factor beta; D014613:Vaccines, Attenuated; D017258:Medroxyprogesterone Acetate